Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma

Por Jebali, M., Elaidi, R., Brizard, M., Fouque, J., Takouchop, C., Sabatier, B., Oudard, S., Medioni, J.
Publicado no BMC Cancer (2017)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

Por Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
Publicado em 2012

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration

Por Bamias, A, Tzannis, K, Beuselinck, B, Oudard, S, Escudier, B, Diosynopoulos, D, Papazisis, K, Lang, H, Wolter, P, de Guillebon, E, Stravodimos, K, Chrisofos, M, Fountzilas, G, Elaidi, R-T, Dimopoulos, M A, Bamia, C
Publicado em 2013

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

Por Beuselinck, B, Jean-Baptiste, J, Couchy, G, Job, S, De Reynies, A, Wolter, P, Théodore, C, Gravis, G, Rousseau, B, Albiges, L, Joniau, S, Verkarre, V, Lerut, E, Patard, J J, Schöffski, P, Méjean, A, Elaidi, R, Oudard, S, Zucman-Rossi, J
Publicado no Br J Cancer (2015)